CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires

El Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC) es una Asociación civil sin fines de lucro, entidad de bien público y universitaria. Nació en 1958 a partir de la visión innovadora del Dr. Norberto Quirno y de un grupo de discípulos comprometidos, que quisieron mejorar la medicina argentina. Esta visión ha convertido a esta institución en líder y referente en el área de la salud.

Av. Galvan 4102, CABA, Buenos Aires

Websitehttp://www.cemic.edu.ar/

Select an option

I am a doctor

I am a sponsor

Specializations

Esclerosis múltiple

Covid-19

Coronavirus

Cáncer

Enfermedad de Crohn

Influenza A

Linfoma

Lupus eritematoso sistémico

Melanoma

Pan Tumor

Poliquistosis renal autosómica dominante

Our team

Medical staff

Julieta Grasselli

Livia Zarini

Jorge Thierer

Juan Ignacio Rojas

Stella Zarza

Nicolás Torresi

Pablo Bonvehí

Vanina Wainsztein

Investigadora PrincipalNicolás Torressi

Alejandro Kuzminin

Aldo Perfetti

Diego Castro

Corina Capparelli

Victoria Marroquin

Florencia Perazzo

Analia Patricia Alvarez

Máximo De la Vega

Pablo Olivera Sendra

Fernando Galanternik

Patricio José Duarte

Open studies

Lung cancer

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVie

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZeneca

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLC

Breast Cancer

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLC

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) - DYNASTY-Breast02 - BioNTech SE

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) - MK-2870-032 - Merck Sharp & Dohme LLC

Bile Duct Cancer

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement - FOENIX-CCA4 - Taiho Oncology, Inc.

Colorectal cancer

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - Amgen

Covid-19

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease - CARR-COV-02 - Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

Epilepsies

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy - RISE 2 - Biohaven Therapeutics Ltd.

Gastrointestinal Cancer

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) - REJOICE-GI01 - Merck Sharp & Dohme LLC

Head and neck cancer

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone - Boehringer Ingelheim

Heart failure

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) - AURORA-HFpEF - Bristol-Myers Squibb

Leukemia

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Lymphoma

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Non-Hodgkin Lymphoma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - Celgene

Prostate cancer

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. - PSMA-DC - Novartis Pharmaceuticals

Rare diseases

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Urothelial cancer

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires

Av. Galvan 4102, CABA, Buenos Aires

Websitehttp://www.cemic.edu.ar/

Select an option

I am a doctor

I am a sponsor

Specializations

Esclerosis múltiple

Covid-19

Coronavirus

Cáncer

Enfermedad de Crohn

Influenza A

Linfoma

Lupus eritematoso sistémico

Melanoma

Pan Tumor

Poliquistosis renal autosómica dominante

Our team

Medical staff

Julieta Grasselli

Livia Zarini

Jorge Thierer

Juan Ignacio Rojas

Stella Zarza

Nicolás Torresi

Pablo Bonvehí

Vanina Wainsztein

Investigadora PrincipalNicolás Torressi

Alejandro Kuzminin

Aldo Perfetti

Diego Castro

Corina Capparelli

Victoria Marroquin

Florencia Perazzo

Analia Patricia Alvarez

Máximo De la Vega

Pablo Olivera Sendra

Fernando Galanternik

Patricio José Duarte

Open studies

Lung cancer

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZeneca

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLC

Breast Cancer

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLC

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) - DYNASTY-Breast02 - BioNTech SE

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) - MK-2870-032 - Merck Sharp & Dohme LLC

Bile Duct Cancer

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement - FOENIX-CCA4 - Taiho Oncology, Inc.

Colorectal cancer

Covid-19

Epilepsies

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy - RISE 2 - Biohaven Therapeutics Ltd.

Gastrointestinal Cancer

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) - REJOICE-GI01 - Merck Sharp & Dohme LLC

Head and neck cancer

Heart failure

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) - AURORA-HFpEF - Bristol-Myers Squibb

Leukemia

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Lymphoma

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Non-Hodgkin Lymphoma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - Celgene

Prostate cancer

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. - PSMA-DC - Novartis Pharmaceuticals

Rare diseases

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.

Urothelial cancer

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads